Lv1
18 积分 2022-12-21 加入
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
5天前
已关闭
KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)
13天前
已完结
KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)
13天前
已关闭
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
13天前
已完结
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
26天前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
2个月前
已完结
"The RAS Dam Has Broken"
4个月前
已关闭
Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy
7个月前
已完结
"Undruggable KRAS": druggable after all
8个月前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
8个月前
已完结
皖公网安备34019202002308
